FLAG Therapeutics is a near-term clinical stage company focused on developing new small molecule therapeutics for difficult-to-treat cancers.

FLAG-003, the company’s lead candidate for the treatment of glioblastoma multiform (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG - a rare and fatal pediatric cancer), is on-track to enter Phase 1 clinical development shortly.

We welcome you to visit our website and contact us directly to learn more about the work we are doing.